Blog Big Molecule Watch July 26, 2018

Dr. Reddy’s Laboratories Announces Launch of HERVYCTA (trastuzumab) in India

Dr. Reddy’s Laboratories Ltd. announced today that it launched HERVYCTA (trastuzumab), a biosimilar of Roche’s HERCEPTIN, in India.  According to the press release, HERVYCTA is indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer), and is available in strengths of 150mg and 440mg multiple dose vials.

The post Dr. Reddy’s Laboratories Announces Launch of HERVYCTA (trastuzumab) in India appeared first on Big Molecule Watch.